CJC-1295 research guide for Crosia. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers looking for CJC-1295 in Crosia soon discover that local retail options are virtually absent. This matters because CJC-1295 quality differs enormously across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor is the entire quality system. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety documentation. The sections below cover what Crosia researchers need to know about finding, evaluating, and storing CJC-1295 for research purposes.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Crosia researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The most effective path to quality CJC-1295 is community research first — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone does not confirm what the compound actually is. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, customer service that can discuss analytical methods, and cold chain packaging that protects product integrity. Bacteriostatic water is the correct reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to approximately one month when stored at 2-8°C.
Order CJC-1295 — ships to Crosia
COA-verified · International tracking · Research grade
All use of CJC-1295 in Crosia or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should follow research laboratory protocols. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; do not freeze and thaw reconstituted CJC-1295 multiple times by aliquoting into single-use portions. The main safety concern arising from sourcing in CJC-1295 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the direct mitigation for this hazard. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
